Q32 Bio (NASDAQ: QTTB) amends Form 4, granting 10,826 options
Rhea-AI Filing Summary
An amended Form 4 for Q32 Bio Inc. reports that director and 10% owner Diyong Xu received a grant of 10,826 stock options on June 12, 2026 at a $12.64 exercise price, vesting by June 12, 2027 or the next annual meeting, with benefits required to be passed through to specified OrbiMed investment entities.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Xu Diyong
Role
Director, 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1, F2, F3 | 10,826 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 10,826 shares (Direct)
Footnotes (3)
- F1. This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
- F2. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
- F3. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.
Key Figures
Stock options granted: 10,826 options
Exercise price: $12.64 per share
Options outstanding after grant: 10,826 options
+2 more
5 metrics
Stock options granted
10,826 options
Grant of stock options to Diyong Xu on June 12, 2026
Exercise price
$12.64 per share
Conversion or exercise price of the stock option grant
Options outstanding after grant
10,826 options
Total derivative securities held directly after the reported grant
Option expiration date
June 11, 2036
Expiration date of the granted stock options
Vesting date
June 12, 2027
Options vest on the earlier of this date or the next annual meeting
Key Terms
Stock Option (Right to Buy), exercise price, vesting, economic benefit, +1 more
5 terms
Stock Option (Right to Buy) financial
"Reported security titled "Stock Option (Right to Buy)" for common stock"
exercise price financial
"Conversion or exercise price of the option is $12.6400 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"Shares underlying this option shall vest and become exercisable in full"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
economic benefit financial
"transfer any securities issued or the economic benefit thereof to OrbiMed"
annual meeting of stockholders regulatory
"vest upon June 12, 2027 or the date of the Issuer's next annual meeting"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Q32 Bio Inc. (QTTB) report for Diyong Xu?
Q32 Bio reported that Diyong Xu, a director and 10% owner, received a grant of 10,826 stock options. These options relate to common stock and represent a new derivative position awarded on June 12, 2026, as shown in the amended insider report.
How many stock options were granted to Diyong Xu in QTTB and at what exercise price?
Diyong Xu was granted 10,826 stock options linked to Q32 Bio common stock at a $12.64 exercise price per share. The options were awarded on June 12, 2026, with no cash paid at grant, reflecting a compensation-related award.
When do Diyong Xu's Q32 Bio (QTTB) options vest and expire?
The options vest in full on the earlier of June 12, 2027 or Q32 Bio’s next annual meeting of stockholders. They are subject to his continued service through that vesting date and carry an expiration date of June 11, 2036.
Why was this Q32 Bio (QTTB) Form 4 amended?
The Form 4 was amended solely to correct the number of options awarded to Diyong Xu on June 12, 2026. The amendment clarifies the accurate grant size of 10,826 options and does not introduce new transactions beyond that correction.
What is the relationship between Diyong Xu's QTTB options and OrbiMed entities?
Under an agreement, Diyong Xu must transfer any securities or economic benefits from these options to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC. Those entities will then ensure the benefits are provided to OrbiMed Private Investments VII, LP.
Were the Q32 Bio (QTTB) insider transactions made under a Rule 10b5-1 plan?
The report indicates the transaction was not made pursuant to a Rule 10b5-1 trading plan, as the relevant checkbox is not selected. No footnote describes a pre-arranged trading plan in connection with this option grant.